Vaxcyte, Inc.
PCVX
$30.25
-$0.20-0.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.42% | -48.09% | 24.18% | -11.29% | -88.33% |
| Total Depreciation and Amortization | 43.44% | 57.68% | 62.31% | 81.09% | 44.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -42.13% | 187.51% | 112.94% | 744.16% | 1,560.57% |
| Change in Net Operating Assets | 532.32% | 32.94% | -106.53% | -14.04% | -412.22% |
| Cash from Operations | 0.19% | -4.49% | 13.52% | -5.49% | -93.48% |
| Capital Expenditure | 74.97% | -121.60% | 47.38% | -418.87% | -1,921.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 311.21% | 134.18% | -1,321.85% | -3,067.48% | 87.66% |
| Cash from Investing | 196.69% | 127.34% | -3,900.92% | -4,215.88% | 75.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.08% | -99.26% | 95.50% | 2,879.91% | -79.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -26.90% | -60.01% | -228.79% | -258.39% | -164.02% |
| Cash from Financing | -97.72% | -99.91% | 79.41% | 3,020.57% | -79.82% |
| Foreign Exchange rate Adjustments | 156.74% | -80.67% | 117.57% | -630.54% | -1,707.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.80% | -119.17% | -348.47% | 3,609.86% | -161.66% |